I got to disagree, a deal before interim results is possible,...

I got to disagree, a deal before interim results is possible, however I believe one after interim results in March much more likely. The reason being is that US puts a big emphasis on proteinuria reduction rather than eGFR. Unlike Aus, Europe and other areas which will require significance in both proteinura and eGFR. I think the company is fairly confident in proteinuria reduction and would be happy to wait for initial proteinuria data in interim readout (i'm pretty sure this is looked at, can anyone confirm?). They should be able to land a very big US deal if a favourable reduction in proteinuria is seen. And ADVANZ PHARMA deal will allow them to hold off until this point. Very well played by the company so far in my opinion.

Also important to note egfr reduction will take longer to see a benefit in - hence the longer timeline in this study. Protein reductions tend to become evident in a much shorter timeline.